A detailed history of Northern Trust Corp transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Northern Trust Corp holds 815,160 shares of FATE stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
815,160
Previous 736,674 10.65%
Holding current value
$1.35 Million
Previous $2.42 Million 18.09%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.12 - $5.57 $244,876 - $437,167
78,486 Added 10.65%
815,160 $2.85 Million
Q2 2024

Aug 14, 2024

BUY
$3.26 - $7.08 $67,227 - $146,003
20,622 Added 2.88%
736,674 $2.42 Million
Q1 2024

May 14, 2024

BUY
$3.54 - $8.35 $26,419 - $62,316
7,463 Added 1.05%
716,052 $5.26 Million
Q4 2023

Feb 13, 2024

SELL
$1.65 - $3.94 $890,377 - $2.13 Million
-539,623 Reduced 43.23%
708,589 $2.65 Million
Q3 2023

Nov 13, 2023

SELL
$2.02 - $5.04 $8,582 - $21,414
-4,249 Reduced 0.34%
1,248,212 $2.65 Million
Q2 2023

Aug 11, 2023

BUY
$4.76 - $6.59 $2.22 Million - $3.08 Million
467,171 Added 59.49%
1,252,461 $5.96 Million
Q1 2023

May 15, 2023

BUY
$4.24 - $11.12 $92,660 - $243,016
21,854 Added 2.86%
785,290 $4.48 Million
Q4 2022

Feb 13, 2023

SELL
$9.86 - $23.83 $42,043 - $101,611
-4,264 Reduced 0.56%
763,436 $7.7 Million
Q3 2022

Nov 14, 2022

SELL
$21.04 - $36.06 $172,675 - $295,944
-8,207 Reduced 1.06%
767,700 $17.2 Million
Q2 2022

Aug 12, 2022

SELL
$17.78 - $42.39 $69,786 - $166,380
-3,925 Reduced 0.5%
775,907 $19.2 Million
Q1 2022

May 13, 2022

SELL
$29.67 - $60.28 $957,599 - $1.95 Million
-32,275 Reduced 3.97%
779,832 $30.2 Million
Q4 2021

Feb 08, 2022

SELL
$47.84 - $64.34 $540,113 - $726,398
-11,290 Reduced 1.37%
812,107 $47.5 Million
Q3 2021

Nov 15, 2021

SELL
$59.27 - $95.73 $3.63 Million - $5.87 Million
-61,283 Reduced 6.93%
823,397 $48.8 Million
Q2 2021

Aug 13, 2021

BUY
$67.25 - $92.52 $172,025 - $236,666
2,558 Added 0.29%
884,680 $76.8 Million
Q1 2021

May 12, 2021

SELL
$72.16 - $117.4 $811,511 - $1.32 Million
-11,246 Reduced 1.26%
882,122 $72.7 Million
Q4 2020

Feb 11, 2021

SELL
$38.09 - $100.95 $923,225 - $2.45 Million
-24,238 Reduced 2.64%
893,368 $81.2 Million
Q3 2020

Nov 16, 2020

BUY
$30.41 - $40.5 $1.18 Million - $1.58 Million
38,911 Added 4.43%
917,606 $36.7 Million
Q2 2020

Aug 14, 2020

BUY
$20.21 - $35.23 $1.6 Million - $2.78 Million
78,975 Added 9.88%
878,695 $30.1 Million
Q1 2020

May 14, 2020

BUY
$17.28 - $31.88 $157,075 - $289,789
9,090 Added 1.15%
799,720 $17.8 Million
Q4 2019

Feb 14, 2020

BUY
$13.39 - $20.73 $1.26 Million - $1.96 Million
94,310 Added 13.54%
790,630 $15.5 Million
Q3 2019

Nov 13, 2019

SELL
$15.47 - $22.5 $872,136 - $1.27 Million
-56,376 Reduced 7.49%
696,320 $10.8 Million
Q2 2019

Aug 13, 2019

BUY
$15.61 - $20.44 $51,887 - $67,942
3,324 Added 0.44%
752,696 $15.3 Million
Q1 2019

May 13, 2019

BUY
$13.15 - $18.71 $182,259 - $259,320
13,860 Added 1.88%
749,372 $13.2 Million
Q4 2018

Feb 12, 2019

BUY
$11.48 - $16.98 $1.27 Million - $1.88 Million
110,936 Added 17.76%
735,512 $9.44 Million
Q3 2018

Nov 14, 2018

BUY
$8.75 - $16.29 $492,660 - $917,192
56,304 Added 9.91%
624,576 $10.2 Million
Q2 2018

Sep 18, 2018

SELL
$9.16 - $13.48 $23,916 - $35,196
-2,611 Reduced 0.46%
568,272 $6.44 Million
Q2 2018

Aug 14, 2018

BUY
$9.16 - $13.48 $677,510 - $997,034
73,964 Added 14.88%
570,883 $6.47 Million
Q1 2018

May 09, 2018

BUY
$6.3 - $13.77 $683,568 - $1.49 Million
108,503 Added 27.93%
496,919 $4.85 Million
Q4 2017

Feb 14, 2018

SELL
$3.94 - $6.64 $17,863 - $30,105
-4,534 Reduced 1.15%
388,416 $2.37 Million
Q3 2017

Nov 13, 2017

BUY
$2.6 - $4.31 $1.02 Million - $1.69 Million
392,950
392,950 $1.56 Million

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.